There's a lot here to unpack. KBT has been in the majority of rulings 72% of the time, the LOWEST of any justice. Turns out that many rulings are in fact 9-0. So there's that.
The ruling is really interesting though. A drug can be patented for many uses, each with a separate patent. The generic maker can produce the drug; but with only some of the indications that the original company has patents for. But doctors often, very often, prescribe meds for "off-label" uses. So this allows a generic to be prescribed for a purpose still under patent. Hence the suit. But the ruling favors the generics. Good for the consumer.
Drug makers have been extending patents by finding "new" indications for their product. This ruling should make the generic make inroads sooner. Yay.